Month: December 2020

Multi-system order for ESI® Geode™ HDI via drilling system to support leading technology in HDI PCB manufacturingPORTLAND, Ore., Dec. 10, 2020 (GLOBE NEWSWIRE) — MKS Instruments, Inc. (NASDAQ: MKSI), a global provider of technologies that enable advanced processes and improve productivity, today announced it has received an order for multiple ESI® Geode™ HDI via drilling systems in Taiwan from a major technology leader in the HDI PCB manufacturing market.“The market is embracing the economic advantages that the latest MKS developments have to offer,” said John Williams, Vice President and General Manager of MKS’ Equipment and Solutions division. “Our Geode HDI via drilling system meets the needs of high-volume HDI PCB manufacturing, while helping customers secure a technological advantage for current and future product requirements.”This...

FALLS CHURCH, Va., Dec. 10, 2020 (GLOBE NEWSWIRE) — PAE (NASDAQ: PAE, PAEWW), a global leader in delivering smart solutions to the U.S. government and its allies, was awarded a single-award indefinite delivery, indefinite quantity contract with a ceiling value of $98 million to provide electronic warfare operations training and infrastructure maintenance support for the U.S. Air Forces in Europe & Air Forces Africa. PAE was also awarded a five-year, €46 million new task order on the contract to operate and maintain USAFE-AFAFRICA’s electronic warfare range systems infrastructure in Germany and provide mobile training operations throughout Europe and Africa.PAE President and CEO John Heller said the company’s past technical experience was key to winning the awards.“PAE has built a unique set of skills and knowledge from...

VANCOUVER, British Columbia, Dec. 10, 2020 (GLOBE NEWSWIRE) — Skyharbour Resources Ltd. (TSX-V:SYH) (OTCQB:SYHBF) (Frankfurt:SC1P) (the “Company”) is pleased to announce that its partner company Azincourt Energy’s (TSX.V: AAZ) ground-based geophysical exploration program at the East Preston uranium project, located in the western Athabasca Basin, Saskatchewan, is now 50% complete.Preston Uranium Project Map:http://skyharbourltd.com/_resources/maps/SYH-Patterson-Lake.pdfThe program is comprised of a horizontal loop electromagnetic survey (“HLEM”) consisting of a total of 33 line-km of line-cutting and surveying. The survey commenced in late November and to date 16.5 line-km have been completed. The survey was originally scheduled for the summer but had been delayed due to Covid-19 restrictions and disruptions.  The HLEM survey is...

BOSTON, Dec. 10, 2020 (GLOBE NEWSWIRE) — X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, today announced that it has received Rare Pediatric Disease (RPD) Designation from the U.S. Food and Drug Administration (FDA) for its lead asset, mavorixafor, for the treatment of WHIM (Warts, Hypogammaglobulinemia, Infections, and Myelokathexis) syndrome, a rare, inherited, primary immunodeficiency disease caused by genetic mutations in the CXCR4 receptor gene. Mavorixafor is currently being investigated in a global pivotal Phase 3 clinical trial, 4WHIM, for the treatment of WHIM syndrome in patients who are 12 years of age and older.“WHIM is a congenital disease that affects individuals of all ages. Children, in particular,...

Approval granted by health authority for the intravenous (IV) formulation of ibrexafungerp to enter Phase 1; dosing in healthy volunteers to start in the first quarter of 2021New interim analysis of the data from the Phase 3 studies of ibrexafungerp in refractory invasive fungal infections (FURI and CARES) expected in the first quarter of 2021; additional 43 patients will double the existing dataset of 41 cases already analyzedAnalysis of the CARES study will provide the first clinical trial data of an investigational treatment against infections caused by Candida auris, a multidrug-resistant fungus deemed an urgent threat by the CDCJERSEY CITY, N.J., Dec. 10, 2020 (GLOBE NEWSWIRE) — SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant...

Bethlehem, PA, Dec. 10, 2020 (GLOBE NEWSWIRE) — Vinco Ventures, Inc. (NASDAQ: BBIG), today updates on the first 30 days of their subsidiary Honey Badger Media, LLC and the advancement of its esteemed influencer list.Honey Badger Media is a digital commerce company and one of Vinco’s key tools in the Be B.I.G. business model. The Company designs digital campaigns from scratch to monetization and leverages a 300 million plus follower network to grow advertiser-based revenue as well as Vinco’s brands and holdings. Additionally, within the first month, Honey Badger was able to sign an impressive catalog of celebrity influencers, including skateboarder and TV personality Bam Margera, Reality Television and Motivational Speaker Adalia Rose, and respected mom blogger Joy of Mom.“We chose Honey Badger as the first platform under our Be...

EMERYVILLE, Calif., Dec. 10, 2020 (GLOBE NEWSWIRE) — XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced it has commenced an underwritten registered public offering of shares of its Series A Cumulative Perpetual Preferred Stock, with liquidation preference of $25.00 per share (the “Preferred Stock”). The Company expects to grant the underwriters a 30-day option to purchase additional shares of the Preferred Stock in connection with the offering.The Company expects to use the net proceeds of this offering to fund the segregated dividend account and the remaining net proceeds for general corporate purposes, including funding future acquisitions of milestone and royalty rights associated with drug development programs with third-party funding.B. Riley Securities, Inc., Ladenburg Thalmann & Co. Inc., National...

Not for distribution by US newswire or in United StatesNESS-ZIONA, Israel, Dec. 10, 2020 (GLOBE NEWSWIRE) — VAXIL BIO LTD. (“Vaxil” or the “Company”) (TSX VENTURE: VXL), an innovative immunotherapy biotech company specializing in cancer and infectious diseases, announces that the Company completed the second and final tranche of its previously announced non-brokered private placement (see press release dated November 9, 2020) for gross proceeds of $264,100 (the “Second Tranche Private Placement“). Investors in the Second Tranche Private Placement subscribed for 3,521,333 units (“Units“) at a price of $0.075 per Unit. Each Unit consisted of one common share in the capital of the Company (“Common Share“) and one Common Share purchase warrant (“Warrant“), with each Warrant being exercisable,...

People with muscle-invasive urothelial cancer (MIUC) who had detectable circulating tumour DNA (ctDNA) were more likely to benefit from treatment with adjuvant (after surgery) Tecentriq monotherapy, compared with those without ctDNAThe goal of current treatment in people with MIUC is to provide early intervention to reduce the risk of the disease recurring or spreading to other parts of the bodyBiomarker analysis from the negative IMvigor010 study broadens our knowledge of cancer immunotherapy in the adjuvant bladder cancer space and could help determine who may benefit most from adjuvant treatment and who may not benefit at allBasel, 10 December 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today presented an exploratory analysis from the Phase III IMvigor010 study evaluating Tecentriq® (atezolizumab), compared with observation, as...

SAN DIEGO, Dec. 10, 2020 (GLOBE NEWSWIRE) — Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in the JMP Securities Hematology Summit. Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in a fireside chat on Tuesday, December 15, 2020 at 11:00 a.m. ET / 8:00 a.m. PT. The virtual forum will be held from December 15-16, 2020.A live audio webcast of the fireside chat will be available in the Investors section of Kura’s website at www.kuraoncology.com, with an archived replay available for 30 days following the event.About Kura OncologyKura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines...